265 related articles for article (PubMed ID: 7655028)
21. Membrane phospholipid asymmetry in human thalassemia.
Kuypers FA; Yuan J; Lewis RA; Snyder LM; Kiefer CR; Bunyaratvej A; Fucharoen S; Ma L; Styles L; de Jong K; Schrier SL
Blood; 1998 Apr; 91(8):3044-51. PubMed ID: 9531618
[TBL] [Abstract][Full Text] [Related]
22. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
Srichairatanakool S; Thephinlap C; Phisalaphong C; Porter JB; Fucharoen S
Med Chem; 2007 Sep; 3(5):469-74. PubMed ID: 17897073
[TBL] [Abstract][Full Text] [Related]
23. Impaired erythrocyte methemoglobin reduction in sickle cell disease: dependence of methemoglobin reduction on reduced nicotinamide adenine dinucleotide content.
Zerez CR; Lachant NA; Tanaka KR
Blood; 1990 Sep; 76(5):1008-14. PubMed ID: 2393709
[TBL] [Abstract][Full Text] [Related]
24. Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload.
Srichairatanakool S; Ounjaijean S; Thephinlap C; Khansuwan U; Phisalpong C; Fucharoen S
Hemoglobin; 2006; 30(2):311-27. PubMed ID: 16798656
[TBL] [Abstract][Full Text] [Related]
25. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand.
Pootrakul P; Sirankapracha P; Sankote J; Kachintorn U; Maungsub W; Sriphen K; Thakernpol K; Atisuk K; Fucharoen S; Chantraluksri U; Shalev O; Hoffbrand AV
Br J Haematol; 2003 Jul; 122(2):305-10. PubMed ID: 12846901
[TBL] [Abstract][Full Text] [Related]
26. Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine.
Mangiagli A; De Sanctis V; Campisi S; Di Silvestro G; Urso L
J Pediatr Endocrinol Metab; 2000 Jun; 13(6):677-80. PubMed ID: 10905396
[TBL] [Abstract][Full Text] [Related]
27. Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice.
Khamseekaew J; Kumfu S; Wongjaikam S; Kerdphoo S; Jaiwongkam T; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
Eur J Pharmacol; 2017 Mar; 799():118-127. PubMed ID: 28192097
[TBL] [Abstract][Full Text] [Related]
28. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
Hoffbrand AV; AL-Refaie F; Davis B; Siritanakatkul N; Jackson BF; Cochrane J; Prescott E; Wonke B
Blood; 1998 Jan; 91(1):295-300. PubMed ID: 9414297
[TBL] [Abstract][Full Text] [Related]
29. Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.
Prus E; Fibach E
Acta Haematol; 2010; 123(1):14-20. PubMed ID: 19923794
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
31. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
Mirbehbahani N; Jahazi A; Rahim Abad HH
Hematology; 2012 May; 17(3):183-6. PubMed ID: 22664119
[TBL] [Abstract][Full Text] [Related]
32. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
Blood; 2001 Feb; 97(3):792-8. PubMed ID: 11157499
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice.
Thephinlap C; Phisalaphong C; Fucharoen S; Porter JB; Srichairatanakool S
Med Chem; 2009 Sep; 5(5):474-82. PubMed ID: 19534681
[TBL] [Abstract][Full Text] [Related]
34. Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment.
Tourkantoni N; Athanassiou-Metaxa M; Zafiriou D; Tzimouli V; Economou M; Taparkou A; Perifanis V; Kanakoudi-Tsakalidou F
Hemoglobin; 2008; 32(1-2):35-40. PubMed ID: 18274981
[TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP
Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.
Hagag AA; Elfaragy MS; Elrifaey SM; Abd El-Lateef AE
Infect Disord Drug Targets; 2015; 15(3):189-95. PubMed ID: 26239735
[TBL] [Abstract][Full Text] [Related]
38. Green tea extract modulates oxidative tissue injury in beta-thalassemic mice by chelation of redox iron and inhibition of lipid peroxidation.
Koonyosying P; Kongkarnka S; Uthaipibull C; Svasti S; Fucharoen S; Srichairatanakool S
Biomed Pharmacother; 2018 Dec; 108():1694-1702. PubMed ID: 30372872
[TBL] [Abstract][Full Text] [Related]
39. Iron chelation therapy.
Hershko CM; Link GM; Konijn AM; Cabantchik ZI
Curr Hematol Rep; 2005 Mar; 4(2):110-6. PubMed ID: 15720959
[TBL] [Abstract][Full Text] [Related]
40. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
